Barinthus Biotherapeutics
(formerly Vaccitech)

NEW FACILITY ANSWERS ACQUISITION AND EXPANSION NEEDS

A spinout of Oxford University, Barinthus Biotherapeutics (formerly Vaccitech) discovers and develops immunotherapeutic products and vaccines for the treatment and prevention of infectious disease and cancer. In 2021, the company expanded with the acquisition of Avidia Technologies in Maryland. The challenge: With the acquisition and with six clinical candidates ready to advance to trials, the company needed a larger facility for a new office headquarters and R&D facility. The solution: Call on VaLogic Owner’s Representation service.

A larger and more effective environment for research

Through Phase I and Phase II Owner’s Representation Services, VaLogic assisted Barinthus Biotherapeutics (formerly Vaccitech) in the successful transition to a larger 16,000-square-foot facility in Germantown, MD, to serve as the company’s new office headquarters and R&D center with a state-of-the-art wet lab. To achieve an optimum outcome, VaLogic was instrumental in strategizing and implementing the timeline and capital investment for the significant and successful expansion.